Paranoid schizophrenia is characterized by increased CB 1 receptor binding in the dorsolateral prefrontal cortex

Neuropsychopharmacology

Volumn 36, Issue 8, 2011, Pages 1620-1630

  Dalton, Victoria S ^a,b   Long, Leonora E ^b,c,d   Weickert, Cyndi Shannon ^b,c,d   Zavitsanou, Katerina ^a,b  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

autoradiography; CB 1 receptor; paranoid schizophrenia; post mortem; real time PCR

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; MESSENGER RNA;

ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PARANOID SCHIZOPHRENIA; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA, PARANOID;

EID: 79958818048     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.43     Document Type: Article

References (53)

1. Ameri A (1999). The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348. (Pubitemid 29230000)
2. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N et al (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845-6856. (Pubitemid 41023152)
3. Ceccarini J, De Hert M, van Winkel R, Koethe D, Bormans G, Leweke M et al (2010). In vivo PET imaging of cerebral type 1 cannabinoid receptor availability in patients with schizophrenia. Schizophrenia Res 117: 170.
4. Chavarría-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori A et al (2008). Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147: 279-284.
5. Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, Chen CH (2008). Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsycho-pharmacol 11: 207-216. (Pubitemid 351231829)
6. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates: Hillsdale, New Jersey.
7. Dalton VS, Wang H, Zavitsanou K (2009). HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 34: 1343-1353.
8. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2: 5.
9. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103: 9-15. (Pubitemid 32304342)
10. Deng C, Han M, Huang X-F (2007). No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull 23: 341-347.
11. D'Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259: 413-431.
12. Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65: 772-784. (Pubitemid 351957703)
13. Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191. (Pubitemid 44973906)
14. Eggan SM, Stoyak SR, Verrico CD, Lewis DA (2010). Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35: 2060-2071.
15. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114. (Pubitemid 39486563)
16. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318. (Pubitemid 27079604)
17. Harper CG, Kril JJ, Daly JM (1988). Brain shrinkage in alcoholics is not caused by changes in hydration: a pathological study. J Neurol Neurosurg Psychiatry 51: 124-127. (Pubitemid 18055114)
18. Harrison PJ, Laatikainen LM, Tunbridge EM, Eastwood SL (2010). Human brain weight is correlated with expression of the 'housekeeping genes' beta-2-microglobulin (beta2M) and TATA-binding protein (TBP). Neuropathol Appl Neurobiol 36: 498-504.
19. Hill C, Keks NA, Roberts S, Opeskin K, Dean B, MacKinnon A et al (1996). Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry 153: 533-537. (Pubitemid 26113318)
20. Keks NA, Hill C, Roberts S, Dean B, Opeskin K, MacKinnon A et al (1997). Diagnostic instrument for brain studies (DIBS). Schizophrenia Res 24: 34.
21. Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F et al (2011). Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 31: 86-91.
22. Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM et al (2007). Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114: 1055-1063. (Pubitemid 47106441)
23. Kozlovsky N, Weickert CS, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G (2004). Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm 111: 1583-1592. (Pubitemid 40064475)
24. Leweke FM, Koethe D, Pahlisch F, Schreiber D, Gerth CW, Nolden BM et al (2009). Antipsychotic effects of cannabidiol. Eur Psychiatry 24(Suppl 1): 207.
25. Liu Q-R, Pan C-H, Hishimoto A, Li C-Y, Xi Z-X, Llorente-Berzal A et al (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 8: 519-530.
26. Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe M et al (2008). Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 28: 2976-2990. (Pubitemid 351442292)
27. Mato S, Pazos A (2004). Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46: 716-726. (Pubitemid 38292976)
28. McGlashan TH, Fenton WS (1991). Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 17: 609-632.
29. Meltzer HY, Arvanitis L, Bauer D, Rein W (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984. (Pubitemid 38735983)
30. Newell KA, Deng C, Huang X-F (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172: 556-560. (Pubitemid 43989359)
31. 2 receptor pharmacology of three plant cannabinoids: (delta)9-tetrahydrocannabinol, cannabidiol and (delta)9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
32. Onaivi ES, Ishiguro H, Gong J-P, Patel S, Perchuk A, Meozzi PA et al (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074: 514-536. (Pubitemid 44532857)
33. Rajkowska G, Goldman-Rakic PS (1995). Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 5: 307-322.
34. Roberts S, Hill C, Dean B, Keks NA, Opeskin K Copolov D (1998). Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust NZ J Psych 32: 73-76. (Pubitemid 28163920)
35. Roser P, Vollenweider FX, Kawohl W (2010). Potential anti-psychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 11(2 Part 2): 208-219.
36. Secher A, Husum H, Holst B, Egerod KL, Mellerup E (2010). Risperidone treatment increases CB1 receptor binding in rat brain. Neuroendocrinology 91: 155-168.
37. Sundram S, Copolov D, Dean B (2005). Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371: 428-433. (Pubitemid 41187515)
38. Sundqvist N, Garrick T, Bishop I, Harper C (2008). Reliability of post-mortem psychiatric diagnosis for neuroscience research. Aust N Z J Psychiatry 42: 221-227. (Pubitemid 351234192)
39. Thacore VR, Shukla SR (1976). Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 33: 383-386.
40. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H et al (2007). No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J 7: 275-281. (Pubitemid 47202490)
41. Ugur T, Bartels M, Kis B, Scherbaum N (2008). Psychosis following anti-obesity treatment with rimonabant. Obes Facts 1: 103-105.
42. Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V et al (2009). Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 206: 313-324.
43. Villares J (2007). Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145: 323-334. (Pubitemid 46237689)
44. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T et al (2010). Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 44: 59-70.
45. Weston-Green K, Huang XF, Han M, Deng C (2008). The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol 11: 827-835.
46. Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE, Sim-Selley LJ (2008). Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology 55: 1183-1190.
47. Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M et al (2010a). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52: 1505-1513.
48. Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS (2010b). Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neu-roscience 169: 1071-1084.
49. Yang Y, Fung SJ, Rothwell A, Tianmei S, Weickert CS (2010). Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol Psychiatry 69: 63-70.
50. Zalewski C, Johnson-Selfridge MT, Ohriner S, Zarrella K, Seltzer JC (1998). A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients. Schizophr Bull 24: 127-145. (Pubitemid 28128494)
51. Zavitsanou K, Garrick T, Huang X-F (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 355-360. (Pubitemid 38130143)
52. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
53. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry 56: 485-486.